

## CURRICULUM VITAE

### **KELLY RENEE ALFORD, MD**

6530 TROOST AVENUE, SUITE A, KANSAS CITY, MO 64131 | 816-361-0670 | KALFORD@KIDNEYKC.COM

#### EDUCATION

University of Kansas – Kansas City, KS

**Doctor of Medicine**

**1999**

Residency – Internal Medicine July 1999-June 2002

Fellowship – Nephrology July 2002-June 2004

Honors:

Intern of the Year – Internal Medicine 1999-2000

Intern of the Year – Bethany Medical Center 1999-2000

Georgetown University – Washington, DC

**Bachelor of Science Foreign Service**

**1985- 1989**

Howard University – Washington, DC

**Language Proficiency, Swahili**

**1988-1989**

Washburn Rural High School – Topeka, KS

**1982-1985**

#### CERTIFICATION AND LICENSURE

American Board of Internal Medicine

**2002 – Present**

American Board of Internal Medicine – Nephrology

**2004 – Present**

Kansas State License No: 29622

**2002 – Present**

Missouri State License No: 2004007601

**2004 – Present**

#### POSITIONS

**Kidney Associates of Kansas City**

**Nephrologist - Partner**

**2004 - Present**

**Dialysis Clinic, Inc. Affiliation**

Rockhill (Medical Director) – 6530 Troost Avenue, Kansas City, MO 64131

Carondelet - 650 Carondelet Drive, Kansas City, MO 64114

Belton – 17045 South Otter Road, Belton, MO 64012

**2004 – Present**

Lee's Summit – 219 NW Executive Way, Lee's Summit, MO 64063

Swope - 2715 Swope Parkway, Kansas City, MO 64130

Warrensburg – 609 E. Young Street, Warrensburg, MO 64093

## RESEARCH EXPERIENCE

Sponsor: Ardelyx, Inc.

**Principal Investigator**

A Randomized, Open-Label Study to Evaluate the Use of Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis who are Phosphate Binder Naïve or on Phosphate Binder Therapy, to Optimize Phosphorus Management (OPTIMIZE).

**Nov 2020 – Present**

Sponsor: Ardelyx, Inc.

**Principal Investigator**

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy in End-Stage Renal Disease (ESRD) Subjects with Hyperphosphatemia.

**February 2019 – Oct 2019**

Sponsor: CARA Therapeutics, Inc.

**Principal Investigator**

An open-label, Multicenter, Study to Evaluate the Safety and Effectiveness of Intravenous CR845 in Hemodialysis Patients with Moderate-to-Severe Pruritus.

**April 2019 – May 2020**

Sponsor: CARA Therapeutics, Inc.

**Principal Investigator**

An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety of Intravenous CR845 in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

**Sept 2017 – Nov 2018**

Sponsor: Baxter Healthcare Corporation

**Principal Investigator**

A Multi-Center, Prospective, Randomized, controlled, Open-label, Parallel Study to Evaluate the Safety and Efficacy of the TheraNova 400 Dialyzer in End Stage Renal Disease (ESRD) Patients

**2017 – Nov 2018**

Sponsor: ZOLL

**Principal Investigator**

WED-HED Study – Wearable Cardioverter Defibrillator in Hemodialysis Patients

**June 2016 – March 2017**

Sponsor: CARA Therapeutics, Inc.

**Principal Investigator**

Two-Part, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients with Moderate-to-Severe Pruritus.

**June 2016 – May 2017**

Sponsor: FibroGen

**Sub- Investigator**

A Phase 3, Open-Label, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects with End stage Renal Disease (ESRD) on Stable Dialysis.

**May 2015 – Dec 2018**

Sponsor: Trevi, Therapeutics

**Sub-Investigator**

An Open-Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Hemodialysis Patients with Uremic Pruritus.

**Oct 2014 – March 2016**

Sponsor: Trevi, Therapeutics

**Sub-Investigator**

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Hemodialysis Patients with Uremic Pruritus.

**July 2014 – Aug 2015**

**MEMBERSHIPS**

American College of Physicians

American Society of Nephrology

National Kidney Foundation